Roche Returns to Hansoh With ADC Partnership Valued at More Than $15 Billion

What happened

Roche has agreed to a broad antibody-drug conjugate (ADC) collaboration with China’s Hansoh Pharma with a total potential value of more than $15 billion including milestones. The agreement was disclosed in a Hansoh stock exchange filing and reported by BioSpace and BioPharma Dive on Monday, Oct. 19.

According to BioSpace, Roche will pay $400 million upfront plus $110 million at the one-year mark. Hansoh can also earn tiered royalties.

Deal details

• Upfront: $400 million, plus a $110 million payment after one year.
• Total potential value: More than $15 billion including milestones.
• Royalties: Tiered royalties to Hansoh.
• Scope: Two existing preclinical ADC programs plus multiple programs against Roche-proposed targets, all using Hansoh’s ADC platform. The total number of programs was not disclosed.
• Division of work: Hansoh develops programs through completion of global Phase 1a trials. Roche handles further development outside mainland China, Hong Kong, Macau and Taiwan.
• Hansoh option: Hansoh can contribute to development outside Asia for two programs and earn additional income from potential U.S. commercialization.

Prior relationship

The agreement deepens an existing partnership. About a year earlier, Roche paid $80 million upfront for licensing rights to HS-20110, a CDH17-targeting ADC with a topoisomerase inhibitor payload for solid tumors, according to BioSpace.

Hansoh has a track record with other Western partners. GSK licensed Hansoh’s HS-20093, risvutatug rezetecan, in late 2023 for $185 million upfront in a deal that could exceed $1.5 billion. The ADC hit its primary overall survival endpoint in a Phase 3 small cell lung cancer study this summer, and China accepted Hansoh’s regulatory submission in early September.

Why it matters for the sector

Antibody-drug conjugates, which link a targeting antibody to a potent payload, have become one of the most heavily pursued modalities in oncology. Chinese developers have built strong ADC platforms and have been prolific licensors of programs to Western drugmakers, often moving from discovery to clinical testing quickly.

The Roche deal stands out for its headline value, which places it among the largest licensing agreements of the year. As with most such deals, the vast majority of that figure is contingent on development and commercial milestones, and the upfront payments are a small fraction of the total.

The structure, in which Hansoh runs early clinical work before handing off, lets Roche benefit from Hansoh’s development speed while limiting its own spending until programs show early clinical data. Hansoh’s option to participate in ex-Asia development and U.S. commercialization for two programs is a sign of Chinese companies seeking a larger share of global value rather than simply out-licensing.

The agreement is part of a run of Roche deals in China. A week earlier, Roche licensed a genetic approach to obesity from Rona Therapeutics in a deal that could exceed $1 billion, according to BioSpace.

The deal also arrived as BioSpace reported that China has tightened oversight of biotech platform ownership while continuing to permit foreign licensing deals, a reminder that regulatory conditions on both sides can affect cross-border transactions.

For Hansoh, upfront and one-year payments totaling $510 million provide substantial non-dilutive capital to fund its ADC platform and early clinical work, and strengthen its position as a repeat partner for large Western drugmakers.

Repeat deals between the same partners can also be read as a signal of satisfaction with earlier collaborations, since the licensee has direct experience of the licensor’s data quality and execution.

What to watch

• Selection of the Roche-proposed targets and the number of programs covered.
• Entry of the two existing preclinical ADC programs into Phase 1a trials.
• Regulatory decisions on Hansoh’s HS-20093 in China and elsewhere.
• Policy developments in the U.S. and China affecting licensing deals.

Sources: BioSpace, BioPharma Dive

Inside an ADC Platform

A company’s ADC “platform” usually refers to its toolkit for the parts of the molecule other than the antibody, and the ways those parts are assembled. Platforms differ along several dimensions:

• Payload. Many newer ADCs use topoisomerase I inhibitors, which damage DNA in dividing cells. Older designs often used microtubule inhibitors, which stop cells from dividing. The payload shapes both effectiveness and side effects.
• Linker. Cleavable linkers release the payload inside the cell or in the tumor environment; non-cleavable linkers release it only after the antibody is broken down. Linker stability in the bloodstream helps limit damage to healthy tissue.
• Drug-to-antibody ratio. The number of payload molecules attached to each antibody. Higher ratios deliver more drug per antibody but can affect stability and tolerability.
• Bystander effect. Some payloads can diffuse out of the target cell to kill neighboring tumor cells that lack the target, which can help in tumors where the target is unevenly expressed.
• Conjugation method. How and where the payload is attached affects consistency and manufacturing.

When a large company licenses programs against its own chosen targets, as Roche is doing here, it is effectively paying to apply another company’s toolkit to its own biology.

The Handoff Point: What Phase 1a Covers

Phase 1 cancer trials are often split into stages. Phase 1a is typically a dose-escalation stage, in which small groups of patients receive increasing doses to find the highest tolerable dose and a recommended dose for further study. Phase 1b usually expands enrollment at chosen doses, often in specific tumor types, to gather more safety data and early signs of activity. Handing off after Phase 1a means Roche would receive programs with an established dose range and initial safety data, then decide which tumor types to pursue.

Keeping the Headline in Perspective

The more than $15 billion figure assumes that many programs succeed across development, regulatory and commercial stages. Upfront and first-year payments of $510 million represent the committed portion. Spread across an undisclosed but multiple-program scope, the per-program milestone potential depends heavily on how many targets are ultimately included, which is why observers focus on the number of programs once it is disclosed.

Questions Readers Ask

What is CDH17?

Cadherin-17 is a cell-surface protein found in gastrointestinal tissues and expressed in some digestive tract cancers, which makes it a candidate ADC target.

Why disclose the deal through a stock exchange filing?

Listed companies must promptly disclose material agreements under exchange rules, so filings are often the first public source of terms.

What does a Phase 3 overall survival win mean?

The drug helped patients in the trial live longer than the comparison treatment, the most important endpoint in many cancer studies. Patients should discuss treatment options with their own oncologists.

This article is for general information only and is not medical or investment advice.